Tezspire shows positive results in a study for eosinophilic esophagitis, potentially becoming its third approved indication. This development could significantly expand its market potential for AstraZeneca and Amgen.
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
Original title: “New data could widen use of AstraZeneca, Amgen immune disease drug”